Healthcare
Tonix Pharmaceuticals Holding Corp.(TNXP)
Live Price
Offline$11.35
+6.57% today
1Y Change
-64.93%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- $190.00M
- Revenue Growth
- +29.8%
- EPS Growth
- +91.7%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tonix Pharmaceuticals Holding Corp. (TNXP) is a Healthcare stock with a market cap of $190.00M and listed on NASDAQ. The stock last traded around $11.35 and down 64.9% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +29.8%, EPS growth of +91.7%, a dividend yield of 0.0%. What stands out right now is revenue +29.8%, EPS +91.7%, free cash flow -69.1% with operating margin -959.1% and ROIC -51.0%. Valuation already assumes a fairly strong business story at price/sales 14.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TNXP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+29.8% vs +7.6% peer median
Operating Margin
Below sector median
-959.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +29.8% and EPS at +91.7%, with operating margin around -959.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +6.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | -5.9% | +1.1% | -18.8% |
2026 Mar 12, 2026 | -25.9% | -1.3% | +17.6% | -6.9% |
2025 Nov 10, 2025 | +0.0% | +4.1% | -0.2% | +16.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TNXP
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TNXP Max Drawdown
-82.70%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TNXP and SPY.
Company Overview
Tonix Pharmaceuticals Holding Corp.
NASDAQ Capital Market
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
- Leadership
- Seth Lederman
- IPO Date
- May 10, 2012
- Employees
- 81
- Street Address
- 26 Main Street
- Mailing
- Chatham, NJ, 07928
- Region
- Chatham, NJ, US
- Reporting Currency
- USD
- Investor Line
- 862 799 8599
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.1
- Price/Sales
- 14.7
- Price/Book
- 0.5
Growth
- Revenue
- +29.8%
- EPS
- +91.7%
- Free Cash Flow
- -69.1%
Profitability
- Gross Margin
- 49.3%
- Operating Margin
- -959.1%
- Net Margin
- -946.2%
- ROE
- -60.2%
- ROIC
- -51.0%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 7.42
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.